Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Benarroch, E. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benarroch, E. E.
NEUROLOGY 2008;71:217-221
© 2008 American Academy of Neurology
Clinical Implications of Neuroscience Research

Descending monoaminergic pain modulation

Bidirectional control and clinical relevance

Eduardo E. Benarroch, MD

From the Mayo Clinic, Department of Neurology, Rochester, MN.

Address correspondence and reprint requests to Dr. Eduardo E. Benarroch, Mayo Clinic, Department of Neurology, 200 First Street SW, West 8A Mayo Bldg, Rochester, MN 55905

GLOSSARY: CGRP = calcitonin gene-related peptide; DAT = dopamine transporter; GABA = {gamma}-aminobutyric acid; NET = norepinephrine transporter; NRM = nucleus raphe magnus; PAG = periaqueductal gray; RLS = restless legs syndrome; RVMM = rostral ventromedial medulla; SERT = serotonin transporter; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; STT = spinothalamic tract.

benarroch.eduardo{at}mayo.edu

Disclosure: The author reports nodisclosures.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.